FMP
Jan 22, 2025 1:32 PM - Davit Kirakosyan
Image credit: FMP
Cerence Inc. (NASDAQ:CRNC) shares rose more than 5% pre-market today after the company received an upgrade from Needham analysts, who assigned a Buy rating and a price target of $16. This upgrade reflects optimism around the company’s potential to benefit from evolving voice technology and strategic industry trends.
The increasing adoption of large language model (LLM)-based voice assistants is expected to boost Cerence’s price-per-unit (PPU) metrics, aligning with automakers’ focus on cost efficiency while preserving their premium branding. According to the analysts, Cerence is well-positioned to capitalize on this convergence due to its innovative technology and market-leading solutions.
Needham cited several factors supporting the upgrade, including the company’s experienced leadership, effective debt management, and robust cash flow expectations driven by deferred revenue. Confidence in the continued rise of PPU rates and the normalization of fixed contract balances by late 2026 further strengthen the growth outlook. Additionally, operating expense estimates appear conservative, suggesting room for upside in near-term financial performance.
While the recent extension of Cerence’s partnership with NVIDIA was not the primary driver of the rating change, the collaboration is expected to bolster Cerence’s software capabilities in the short term. According to the analysts, over the longer term, this partnership could pave the way for unique edge LLM applications and an enhanced go-to-market strategy.
Jan 22, 2025 8:26 AM - Davit Kirakosyan
Cantor Fitzgerald analysts reiterated an Overweight rating on Amazon.com (NASDAQ:AMZN), maintaining a price target of $270 on the stock. The outlook highlights Amazon’s robust positioning among mega-cap names, with potential upside in key metrics for both the fourth quarter of 2024 and the first qua...
Jan 22, 2025 8:45 AM - Davit Kirakosyan
Johnson & Johnson (NYSE:JNJ) delivered fourth-quarter results that surpassed Wall Street expectations, driven by robust demand for its cancer treatments and strategic acquisitions. The pharmaceutical giant also provided an upbeat forecast for 2025, projecting full-year sales of $90.9 billion to $91....